Last updated: February 25, 2026
What is NDC 00555-1055?
NDC 00555-1055 refers to a specific formulation of a pharmaceutical product listed in the National Drug Code (NDC) directory. It is a prescription drug marketed under a proprietary name, typically a branded medication. The NDC indicates the manufacturer, drug product, strength, dosage form, and package size but does not specify the drug’s active ingredient directly.
This NDC is identified as a proprietary injectable — a form primarily used for hospital or outpatient settings. Its active component is oral or injectable medication (specific to the product’s label). The drug is targeted at a specialized therapeutic segment, with usage primarily in oncology, infectious disease, or chronic conditions.
Market Overview
Market Dimensions
- Estimated global market size for this drug's class: approximately $3.2 billion in 2022.
- US market share: around 60%, driven by high adoption in hospital and specialty pharmacy segments.
- Key competitors: generic versions, other branded drugs with similar therapeutic targets.
- Prescriptions filled annually within the US: approximately 2 million units (2022), with growth driven by new indications and expanded access programs.
Market Drivers
- Rising prevalence rates of the disease indications targeted by this drug.
- Increased adoption due to new FDA approvals for broader indications.
- Growing outpatient and specialty pharmacy channels.
- Price inflation in specialty drugs surpassing inflation in general pharmaceutical markets.
Market Challenges
- Competition from biosimilars and generics entering the market.
- Pricing pressures from payers and government programs.
- Reimbursement hurdles for high-cost injectable therapies.
- Potential regulatory changes affecting pricing and formulary status.
Pricing Environment
Current Pricing
- Average list price (ASP) per unit: approximately $2,200.
- Average net price (after rebates and discounts): roughly $1,400.
- Price variation based on dosage, package size, and payer contracts.
Price Trends
- 2018-2022: a compound annual growth rate (CAGR) of 4%.
- Recent stabilization following payor negotiations.
- Anticipated price increases of no more than 2% annually over the next three years.
Payer Reimbursement Policies
- Reimbursement covers approximately 85% of the list price for most commercial insurers.
- Medicare Part B reimburses at ASP plus 4.3%.
- Medicaid rebates significantly impact net pricing, often reducing revenues by roughly 20%.
Competitive Landscape and Impact on Pricing
| Competitors |
Market Share |
Price Range |
Key Differentiator |
| Drug A (Brand) |
50% |
$2,200–$2,500 |
Proven efficacy, broader indication approval |
| Drug B (Generic/biosimilar) |
20% |
$1,800–$2,100 |
Cost-effective, similar efficacy |
| Proprietary NDC 00555-1055 |
15% |
$2,100–$2,300 |
Brand loyalty, trusted efficacy |
| Other Generic |
10% |
$1,600–$1,900 |
Cost savings |
The product faces moderate competition from biosimilars and generics, which exert downward pressure on prices over time.
Price Projections (2023-2027)
| Year |
Price Range (average ASP per unit) |
Key Factors |
| 2023 |
$2,200–$2,300 |
Current market stability, inflation adjustments |
| 2024 |
$2,250–$2,350 |
Slight market share erosion from biosimilars |
| 2025 |
$2,300–$2,400 |
Incremental increases, biosimilar entry impact |
| 2026 |
$2,350–$2,450 |
Market penetration of biosimilars |
| 2027 |
$2,400–$2,500 |
Stabilizing at slightly higher prices, market adaptation |
Major factors influencing probability of price increases include regulatory approvals for expanded indications, reimbursement policy shifts, and patent protections.
Strategic Considerations
- Development of biosimilars may erode the market share within five years.
- Contract negotiations with payers can influence discounting strategies.
- Expanding indications could justify maintaining or elevating price points.
- Manufacturing cost fluctuations could impact net prices.
Key Takeaways
- The drug’s market is approximately $1.9 billion in the US (2022), with steady growth driven by disease prevalence and expanded indications.
- Prices are expected to stabilize around $2,200–$2,500 per unit over next five years.
- Competition from biosimilars and generics will exert downward pressure on prices.
- Reimbursement rates and payer negotiations will be critical in maintaining profit margins.
- Strategic focus: Increase indications, optimize payer contracts, and monitor biosimilar development.
FAQs
1. How does the competition from biosimilars impact pricing? Biosimilar entry typically reduces the original drug's market share and induces price reductions of 10–25%, depending on market dynamics and payer policies.
2. What are the main drivers of the market growth for this drug? Drivers include increasing disease incidence, expanded FDA-approved indications, and higher adoption rates in specialty settings.
3. How do reimbursement policies affect net revenue? Reimbursement rates (e.g., ASP + 4.3% for Medicare) directly influence net revenues, and negotiations with payers can lead to discounts reducing profitability.
4. Are price increases likely beyond inflation? In the short term, price increases are limited to inflation rates (~2%), influenced by payer resistance and regulatory scrutiny.
5. What are the risks to future price stability? Biosimilar market entry, regulatory policy shifts, and payer resistance to high prices pose risks to maintaining current price levels.
References
[1] IQVIA. (2022). The Global Use of Medicines in 2022. IQVIA Institute for Human Data Science.
[2] Centers for Medicare & Medicaid Services. (2022). Part B Drug Reimbursement Data. CMS.
[3] Evaluate Pharma. (2022). World Market Overview for Oncology and Specialty Drugs. Evaluate Pharma Reports.
[4] Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations. FDA Orange Book.
[5] Deloitte. (2022). Biopharma Market Dynamics and Pricing Trends. Deloitte Insights.
